U.S. markets closed

Shanghai Medicilon Inc. (688202.SS)

Shanghai - Shanghai Precio retrasado. Moneda en CNY.
Añadir a la lista de seguimiento
29.69-0.92 (-3.01%)
Al cierre: 03:00PM CST

Shanghai Medicilon Inc.

585 Chuanda Road
Shanghai 201299
China
86 21 5859 1500
https://www.medicilon.com.cn

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo2,600

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Chunlin Chen Ph.D.Co-Founder, CEO & Executive DirectorN/DN/D1962
Ms. Binbin LiuChief Financial OfficerN/DN/D1977
Mr. Shuangqing Peng Ph.D.Chief Scientific Officer & Core Technical StaffN/DN/D1962
Dr. Jinna Cai Ph.D.Chief Commercial Officer, Deputy GM & DirectorN/DN/D1964
Mr. Chao XueBoard SecretaryN/DN/D1982
Ms. Jiang Xu MBAManager of Human Resources DepartmentN/DN/DN/D
Dr. Jian Liu Ph.D.President of Drug Discovery DivisionN/DN/DN/D
Dr. Haizhou ZhangPresident of Preclinical R&D UnitN/DN/DN/D
Dr. Qingcong LinPresident of Medicilon USA CorpN/DN/D1965
Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en CNY.

Descripción

Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems. In addition, it offers pharmacology services, including cancer xenograft, metabolic disease, inflammation and immunological, neurological disorders, and other disease models; services in the areas of in vitro ADME and in vivo pharmacokinetics; and bioanalytical services, such as large and small molecule services. Further, the company provides preclinical services comprising preclinical pharmacokinetic and safety evaluation. Shanghai Medicilon Inc. was founded in 2004 and is headquartered in Shanghai, China.

Gestión corporativa

La calificación ISS Governance QuickScore de Shanghai Medicilon Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.